CD8A and neoplasm: Anti-CD4 monoclonal antibody, a prominent immunomodulatory agent, elicits robust anti-tumor immunity in various cancers by increasing tumor-infiltrating lymphocytes (TILs)3–5 and promoting CD8+ T-cell reactivity against tumor cell-derived antigens6,7.